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Abstract
Background  and  objective:  Evaluate  the  antinociceptive  effects  of  subarachnoid  meloxicam  on
the mechanical  hypernociception  induced  by  carrageenan  in  rats.
Methods:  Randomized  controlled  trial.  Eighteen  adult  male  Wistar  rats  underwent  a  cannula
implantation  into  the  subarachnoid  space  and  were  randomly  divided  into  two  groups:  Group  I
received saline  solution  5  L,  while  Group  II  received  meloxicam  30  mg.  The  mechanical  hyper-
nociception  was  induced  by  intraplantar  injection  of  carrageenan  and  evaluated  using  a  digital
analgesy meter  every  30  min  during  a  4-h  period.  The  results  were  recorded  as  the    with-
drawal threshold  (in  g),  calculated  by  subtracting  the  measurement  value  after  treatment  from
baseline.
Results: The    withdrawal  threshold  mean  values  were  lower  in  the  group  of  patients  treated
with meloxicam  over  all  time  points  between  45  and  165  min,  however,  there  was  no  statistical
signiﬁcance  (p  =  0.835)  for  this  difference.
Conclusion:  Subarachnoid  meloxicam  at  a  dose  of  30  g  animal−1 did  not  suppress  the  mechan-
ical hypernociception  in  a  model  of  inﬂammatory  pain  induced  by  intraplantar  administration
of carrageenan  in  rats.  The  data  suggest  that  other  dosages  should  be  investigated  the  drug
effect is  discarded.
©  2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
 Work conducted at Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.
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Meloxicam  subaracnoide  não  inibe  a  hipernocicepc¸ão  mecânica  no  teste  da
carragenina  em  ratos
Resumo
Justiﬁcativa  e  objetivo:  avaliar  os  efeitos  antinociceptivos  do  meloxicam  subaracnóideo  sobre
a hipernocicepc¸ão  mecânica  induzida  pela  carragenina  em  ratos.
Métodos:  estudo  randômico  e  controlado.  Dezoito  ratos  Wistar,  machos  adultos,  foram  submeti-
dos à  implantac¸ão  de  uma  cânula  subaracnóidea,  e  aleatoriamente  distribuídos  em  dois  grupos:
o Grupo  I (GI)  recebeu  5  L  de  soluc¸ão  salina,  enquanto  que  ao  Grupo  II  (GII)  foram  administrados
30 g  de  meloxicam,  ambos  pela  via  subaracnóidea.  A  hipernocicepc¸ão  mecânica  foi  induzida
pela injec¸ão  intraplantar  de  carragenina  e  avaliada  com  o  emprego  de  um  analgesímetro  digital
a cada  30  minutos  durante  um  período  de  4  horas.  Os  resultados  foram  registrados  como  o    do
limiar de  retirada  (g),  calculado  subtraindo-se  o  valor  das  mensurac¸ões  após  os  tratamentos,
do valor  basal.
Resultados:  os  valores  médios  do    do  limiar  de  retirada  foram  menores  no  grupo  tratado  com
meloxicam  ao  longo  de  todos  os  momentos  de  avaliac¸ão  entre  45  e  165  minutos,  contudo  não
foi demonstrada  signiﬁcância  estatística  (p  =  0,835)  para  essa  diferenc¸a.
Conclusão:  a  administrac¸ão  subaracnóidea  do  meloxicam  na  dose  de  30  g.animal-1 não  foi
capaz de  suprimir  a  hipernocicepc¸ão  mecânica  em  um  modelo  de  dor  inﬂamatória  induzida
pela administrac¸ão  intraplantar  de  carragenina  em  ratos.  Os  dados  sugerem  que  outras  doses
sejam pesquisadas  antes  que  o  efeito  do  fármaco  seja  descartado.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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Evidence  has  shown  that  besides  the  known  peripheral
action  nonsteroidal  anti-inﬂammatory  drugs  (NSAIDs)  have
a  powerful  effect  on  experimental  pain  that  is  independent
of  its  anti-inﬂammatory  effects.1 In  addition  to  its  periph-
eral  inhibition  of  prostaglandin  synthesis,  a  central  action  of
NSAIDs  has  been  suggested  by  experimental  studies  in  which
these  drugs  demonstrated  greater  potency  by  subarach-
noid  administration  compared  to  systemic  administration.2,3
Studies  have  shown  that  both  cyclooxygenase  (COX)  forms
are  constitutively  expressed  in  the  brain  and  spinal  cord  of
rats,4 with  COX-2  the  predominant  isoform  in  the  spinal  cord
dorsal  horn.5 Spinal  administration  of  anti-inﬂammatory
drugs  has  shown  to  suppress  the  reﬂection  of  C  ﬁbers,  inhibit
neuronal  sensitization  in  the  spinal  cord  dorsal  horn,  and
attenuate  long-term  inﬂammatory  pain.2,6--11
Meloxicam  is  an  analgesic  and  nonsteroidal  anti-
inﬂammatory  drug,  which  belongs  to  the  phenolic  acid  class
and  has  a  preference  for  COX-2  isoenzyme.12 Unlike  many
other  NSAIDs,  it  has  high  oral  bioavailability  and  a  long
half-life,  although  not  free  from  side  effects.13 Studies  of
meloxicam  administered  by  spinal  pathways  are  scarce14--17
and  do  not  assess  its  effects  on  acute  inﬂammatory  pain.
The  aim  of  this  study  was  to  evaluate  the  antinociceptive
power  of  subarachnoid  meloxicam  on  acute  pain  induced  by
carrageenan  in  rats.Materials and methods
The  experimental  protocol  was  reviewed  and  approved
by  the  Animal  Experimentation  Ethics  Committee  of  the
m
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wnstitution.  Rats  were  individually  housed  under  controlled
emperature  (21--24 ◦C)  and  light--dark  cycle  of  12  h,  with
ood  and  water  ad  libitum  offered  for  at  least  14  days.
The  animals  were  surgically  prepared  under  anesthesia
ith  intraperitoneal  injections  of  ketamine  and  xylazine
100  and  10  mg  kg−1,  respectively);  then,  a  cannula  was
mplanted  in  the  subarachnoid  space,  according  to  a  mod-
ﬁcation  of  the  technique  previously  described  in  the
iterature.18 Brieﬂy,  the  animals  were  placed  in  prone  posi-
ion,  with  the  fore  and  hind  limbs  ﬁxed  in  abduction  and  the
egion  of  the  head  slightly  elevated  relative  to  the  rest  of
he  body.  After  skin  antisepsis  of  atlantooccipital  region,  a
ertical  incision  approximately  2  cm  in  length  was  made  in
he  region  midline,  starting  at  the  point  between  the  ears
nd  extending  caudally.  The  subcutaneous  tissue  and  biven-
er  cervicis  and  rectus  capitis  dorsalis  major  muscles  were
emoved  by  blunt  dissection.  With  the  muscular  retraction,
he  dura  and  cisterna  magna  were  seen,  and  after  expo-
ure  of  atlantooccipital  membrane,  an  18  G  needle  was  used
o  puncture  its  central  region,  until  cerebrospinal  ﬂuid  is
een.  A  PE-10  polyethylene  cannula  (#BB31695-PE/1,  Sci-
ntiﬁc  Commodities,  Lake  Havasu  City  --  AZ,  USA)  was  then
nserted  through  the  hole  and  advanced  caudally  8.5  cm  into
he  subarachnoid  space  until  it  reaches  the  lumbar  enlarge-
ent  region.  Measuring,  cutting,  and  marking  of  cannulas
ith  enamel  paint  were  conducted  prior  to  the  experiment
eriod,  with  this  material  individually  packaged  and  steril-
zed  with  ethylene  oxide.  The  cranial  portion  of  the  cannula
as  inserted  through  an  18  G  needle,  allowing  its  accom-
odation  in  the  subcutaneous  tissue,  in  order  to  emergerom  the  skin  near  the  top  of  the  head.  Muscles  and  skin
ere  sutured  and  the  catheter  external  end  was  occluded
ith  the  insertion  of  a  small  fragment  of  dental  needle
1 L.F.L.  Moura  et  al.
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Table  1  Mean  difference,  standard  error,  and  p-value  of  
withdrawal  threshold  (g)  in  rats  from  GI  and  GII  at  differ-
ent time  points  of  hypernociception  induced  by  intraplantar
injection  of  carrageenan.
Time  points  Estimated  mean
difference
Standard
error
p
30--60  min  −4.13  3.38  0.914
30--90 min  −5.60  3.82  0.813
30--120 min  −7.59  2.96  0.234
30--150 min  −13.64  4.03  0.055
30--180 min  −15.30  4.24  0.036
30--210 min −23.50  3.68  <0.001
30--240 min −27.76 2.53 <0.001
60--90 min  −1.47  2.42  0.998
60--120 min  −3.46  2.58  0.872
60--150 min  −9.51  3.13  0.104
60--180 min  −11.16  3.67  0.104
60--210 min  −19.37  2.71  <0.001
60--240 min  −23.63  2.88  <0.001
90--120 min  −1.99  2.84  0.996
90--150 min  −8.04  2.67  0.111
90--180 min  −9.70  3.35  0.136
90--210 min  −17.90  2.71  <0.001
90--240 min  −22.16  2.99  <0.001
120--150 min  −6.06  2.41  0.254
120--180 min  −7.71  3.81  0.497
120--210 min  −15.92  2.22  <0.001
120--240 min  −20.18  2.80  <0.001
150--180 min  −1.65  3.37  1.000
150--210 min  −9.86  2.60  0.025
150--240 min  −14.12  3.02  0.004
180--210 min −8.21  2.36  0.046
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30  G  ×  21  mm).  Finally,  the  outer  portion  of  the  cannula  was
xed  to  the  skin  with  sutures.  During  the  period  that  fol-
owed  the  cannula  implantation,  the  animals  were  kept  in
ndividual  plastic  boxes  under  the  same  conditions  of  the
revious  period.  On  the  day  following  the  cannula  place-
ent,  the  animals  were  assessed  for  neurological  deﬁcits.
hose  with  neurological  abnormalities  were  excluded  from
he  study.
Eighteen  Wistar  rats,  weighing  300--450  g  were  success-
ully  prepared  for  the  study  and,  one  day  after  the  cannula
lacement,  they  were  tested  for  mechanical  hypernoci-
eption  induced  by  carrageenan.  For  this  purpose,  we
sed  a  digital  analgesy  meter  (Insight  Scientiﬁc  Equipment
tda,  Ribeirão  Preto  -- SP,  Brazil),  according  to  a  previ-
usly  described  technique,19 in  which  a  pressure  transducer
quipped  with  a  7  mm2 polypropylene  tip  was  applied  per-
endicular  to  the  right  plantar  surface  of  the  animals,  with
 linearly  increasing  pressure.  The  equipment  recorded  the
orce  in  grams  (g)  with  a  precision  of  0.1  g.  The  animal
imb  stimulation  was  repeated  until  obtaining  three  simi-
ar  measurements  (the  difference  between  the  highest  and
he  lowest  value  was  less  than  10  g).  Thus,  the  nocicep-
ive  behavior  was  quantiﬁed  by  averaging  the  three  values
xpressed  in  grams,  which  represents  the  paw  withdrawal
hreshold  to  the  mechanical  stimulation  at  each  time  point.
imb  withdrawal  from  contact  with  the  tip  or  shaking  and/or
icking  behavior  at  the  time  or  immediately  after  stimula-
ion  (ﬂinch)  was  considered  positive  response.  Ambulation
as  considered  an  ambiguous  response;  therefore,  when
t  occurred  at  the  time  of  test  application,  the  test  was
epeated.
About  30  min  before  starting  the  assessment,  the  rats
ere  transferred  to  the  testing  place,  consisting  of  acrylic
oxes  with  malleable  wire  mesh  ﬂoor,  in  a  quiet  room,
llowing  its  acclimatization  evidenced  by  cessation  of  the
rooming  and  site  exploration  behavior.  Throughout  this
eriod,  approximately  ﬁve  stimulations  of  animal  limbs  were
erformed,  in  order  to  allow  their  familiarity  with  the  stimu-
us  applied.  Subsequently,  baseline  values  from  each  animal
ere  established.
After  registration  of  baseline  values,  the  animals  were
anually  restrained  and  the  metal  fragment  the  occluding
he  catheter  was  removed.  Next,  the  animals  were  random-
zed  into  two  groups.  Animals  in  Group  I  (GI,  n  =  9)  underwent
ubarachnoid  administration  of  5  L  saline  solution,  while
nimals  in  Group  II  (GII,  n  =  9)  received  meloxicam  30  g
iluted  in  saline  to  a  ﬁnal  volume  of  5  L,  by  the  same
oute.  Solutions  were  administered  with  the  aid  of  a Hamil-
on  10  L  microsyringe  (701N,  Hamilton  Company,  Reno  --
V,  USA)  over  a  period  of  30  s,  after  which,  10  L  sterile
aline  was  injected  to  ﬂush  the  catheter.
Immediately  after  substance  administration  into  sub-
rachnoid  space,  lambda-carrageenan  (0.1  mL  of  2.5%
arrageenan)  was  injected  into  the  intraplantar  region  of
he  right  limb,  following  the  technique  previously  described
n  the  literature.20 The  carrageenan  injection  time  was
ecorded  as  time-zero  (T0),  and  subsequent  evaluations
ere  performed  every  30  min  during  the  4  h  post-drug
dministration  to  obtain  its  temporal  proﬁle  of  action.  All
ssessments  were  performed  by  an  investigator  who  was
lind  to  animal  treatment.  Because  the  animals  were  tested
n  the  periods  before  and  after  the  administration  of  drugs,
c
l
p180--240 min −12.47 3.03  0.013
210--240 min −4.26  2.48  0.677
he  results  were  recorded  as  the    withdrawal  threshold
g),  calculated  by  subtracting  the  measurement  value  after
reatments  from  the  baseline  value,  and  these  values  were
ompared.
Data  are  expressed  as  mean  ±  standard  deviation.  The
 withdrawal  values  were  compared  using  variance  analy-
is  with  repeated  measures  and  two  factors,  with  GI  or  GII
roup  as  the  ﬁxed  factor  and  the  time  (every  30  min)  as  the
epetition  factor.  For  analysis,  an  unstructured  correlation
atrix  between  time  points  was  supposed.  Analyses  were
erformed  with  SAS  software  version  8.0  for  Windows,  and
he  level  of  signiﬁcance  was  determined  at  p  <  0.05.
esults
 mean  increase  of  the    withdrawal  threshold  occurred
ver  time,  with  statistically  higher  values  in  assessments  at
10  and  240  min  compared  to  other  time  points  (p  <  0.05).
here  were  differences  between  other  time  points,  always
ith  a  mean  increase  of    withdrawal  threshold  in  the
ourse  of  the  experiment,  as  shown  in  Table  1.
The  mean  values  of  the    withdrawal  threshold  were
ower  in  the  group  treated  with  meloxicam  over  all  time
oints  between  45  and  165  min,  although  not  statistically
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Figure  1  Mean  values  of    withdrawal  threshold  ±  standard
deviation  (g)  in  different  time  points  of  mechanical  hypernoci-
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tception  in  rats  after  SA  administration  of  saline  solution  (GI)  or
meloxicam  (GII).
signiﬁcant  (p  =  0.835)  for  this  difference  (Fig.  1).  Mean  dif-
ferences  in  the    withdrawal  threshold  occurred  between
time  points  within  each  group  (p  <  0.001).
During  antinociception  evaluation,  two  rats,  both  from
GI,  showed  clinically  differentiated  responses  after  induc-
tion  of  hyperalgesia.  These  animals  presented  with  eye
discharge,  signiﬁcant  prostration,  with  vocalization  at  rest
and  reluctant  to  rest  the  limb  subjected  to  carrageenan
application,  suggesting  the  presence  of  severe  pain.  The
antinociceptive  evaluation  for  these  rats  showed  a  high
degree  of  difﬁculty  compared  to  others,  as  the  animals  did
not  allow  force  to  be  exerted  against  the  plantar  surface
during  measurements.  In  these  cases,  the  animals  raised
their  affected  limb,  following  the  tip  movement,  not  exert-
ing  pressure  resistance.  As  a  result,  these  animals  showed
high  levels  of  withdrawal  threshold,  which  were  not  consis-
tent  with  what  could  be  observed  clinically.
Discussion
The  effectiveness  of  conventional  NSAIDs,  COX-2  inhibitors,
and  monoclonal  anti-prostaglandin  E2  as  anti-inﬂammatory
agents  in  experimental  models  using  carrageenan  is  well
described  in  the  literature.20--22 The  actions  were  tradi-
tionally  assigned  to  peripheral  prostaglandin  inhibition,
which  play  an  important  role  in  nociceptor  sensitization
at  the  site  of  injury,23 as  carrageenan  intraplantar  injec-
tion  induces  a  signiﬁcant  increase  of  COX-2  expression,  as
well  as  prostaglandin  E2  production.24 However,  the  relative
amounts  of  each  isoform  expressed  in  different  tissues  vary
and  may  be  modulated  in  pathological  conditions.  Thus,  in
contrast  to  other  organs,  the  rat’s  normal  brain,  as  well  as
the  spinal  cord,  expresses  more  COX-2  than  COX-1,25 and
data  conﬁrm  its  role  in  the  sensory  processing  of  pain.26
Thus,  a  series  of  experimental  evidence  currently  suggests
that  NSAIDs  exert  their  analgesic  action  also  by  activity  on
the  central  nervous  system,  in  addition  to  its  well-known
peripheral  action.25
Several  drugs  have  been  administered  by  spinal  route  in
an  attempt  to  prove  such  a  mechanism,  and  the  lack  of
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eloxicam  consistent  effects  on  spinal  nociception  induced
n  the  experimental  model  used  contradicts  the  ﬁndings  of
ther  authors  who  reported  antinociceptive  activity  after
pinal  use  of  other  NSAIDs.2,14,15,20,27--32 It  is  noteworthy,
owever,  that  although  there  are  a variety  of  studies  eval-
ating  the  antinociceptive  power  of  COX-2  administered
n  the  subarachnoid  space,  studies  speciﬁcally  investigat-
ng  the  effects  of  meloxicam  are  still  scarce.  These  studies
ave  found  an  inhibitory  effect  on  the  wind-up  phenomenon
n  vitro,33 as  well  as  on  nociception  induced  by  capsaicin
r  formalin.34 Additionally,  a  synergistic  analgesic  effect
ith  morphine  was  found  after  its  SA  administration  in
nimals  with  experimental  visceral  pain.15 In  a  previous
tudy,17 a  dose  similar  to  the  one  used  in  the  present  study
30  g  animal−1)  was  used  to  investigate  the  antiallodynic
ffects  of  SA  meloxicam.  The  authors,  however,  used  an
xperimental  model  of  neuropathic  pain  in  diabetic  mice,
iffering  from  this  study  inﬂammatory  pain  model.  However,
he  drug  effects  were  demonstrated  with  the  dose  used,
hich  did  not  occur  in  this  study.  Observing  carefully  the
ata  shown  in  Fig.  1, one  can  see  that  the  group  receiving
eloxicam  showed  mean  values  of    withdrawal  thresh-
ld  lower  than  those  shown  by  the  group  receiving  saline
olution  during  all  time  points  between  45  and  165  min.
The  intraplantar  carrageenan  inﬂammation  is  charac-
erized  by  a  biphasic  behavior  with  respect  to  swelling.
he  early  phase  (0--1  h)  has  been  attributed  to  the  release
f  histamine,  5-hydroxytryptamine,  and  bradykinin,  so  the
ffectiveness  of  NSAIDs  in  this  period  has  been  questioned.
n  the  late  phase  (1--6  h),  on  the  other  hand,  a high  produc-
ion  of  PGs  has  been  veriﬁed.35 However,  hyperalgesia  seems
o  develop  in  parallel  with  the  increase  of  COX-2  spinal  lev-
ls,  and  its  peak  only  occurs  within  4  h  after  carrageenan
njection.36 Looking  at  Fig.  1,  however,  one  can  see  that  the
ffects  of  meloxicam  on  hyperalgesia  occurred  precisely  in
he  period  prior  to  the  4  h  of  assessment,  with  signiﬁcantly
igher  values  of    withdrawal  threshold  after  165  min  of
dministration,  which  differs  from  such  statements.
However,  this  response  curve  behavior  has  also  been
bserved  in  studies  using  carrageenan  model,  which
eported  anti-hyperalgesic  thermal  effects  with  SA  adminis-
ration  of  SC58125  --  a  selective  COX-2  inhibitor  --  only  during
he  ﬁrst  170  min  of  evaluation.37 As  thermal  hyperalgesia
as  been  shown  to  be  similarly  mediated  by  the  action
f  spinal  COX-2,38 studies  that  characterize  the  pattern  of
pinal  COX-2  expression  in  carrageenan-induced  inﬂamma-
ion,  hitherto  seemingly  nonexistent,  may  help  to  elucidate
uch  observations.  A  signiﬁcant  increase  in  the  hypernoci-
eption  intensity,  characterized  by  increased    withdrawal
hreshold,  especially  in  assessments  at  210  and  240  min,  was
bserved  in  both  experimental  groups.  These  ﬁndings  may
e  explained  by  other  authors  who  report  that  the  repe-
ition  of  mechanical  stimulation  can  produce  an  increased
ensitivity  of  the  stimulated  area.39 Thus,  the  administra-
ion  of  meloxicam  also  failed  to  prevent  the  increase  of
ypernociception  over  time.
Among  the  different  factors  that  may  have  inﬂuenced
his  study  outcomes,  the  establishment  of  an  adequate  dose
as  emerged  as  an  essential  need  whose  importance  may
ave  been  decisive  for  the  data  presented  here.  Currently,
ew  studies  of  subarachnoid  meloxicam  involve  administra-
ion  protocols  distinct  from  that  recommended  in  this  study,
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uch  as  continuous  infusion  techniques16 or  its  association
ith  opioids.15 The  need  to  determine  a  dose  that  shows
onsistent  effects,  or  even  the  absence  of  such  effects,  was
ased  on  the  extrapolation  of  results  obtained  in  these  stud-
es  and  their  suitability  to  the  needs  of  this  work.  Thus,
ased  on  previous  studies  that  showed  satisfactory  results
sing  30-g  animal−1 of  subarachnoid  meloxicam  on  exper-
mental  neuropathic  pain  in  diabetic  animals,17 a  similar
ose  was  recommended  in  order  to  observe  its  effects  on
nﬂammatory  hyperalgesia.
Neuropathic  pain,  however,  is  a  complex  syndrome
nvolving  inﬂammatory  and  immune  theories  yet  to  be
nderstood,  and  whose  hyperalgesia  results  from  both  neu-
al  and  non-neural  tissue  involvement  and  is  associated  with
  and  A  ﬁbers  activation.40 However,  the  nociceptive  sys-
em  complexity  has  shown  that  different  sensory  pathways
re  activated  after  minimal  changes  in  the  nature  of  a
ainful  process,41 leading  to  believe  that  different  doses
f  the  same  drug  may  be  required  for  suppression  of  pain
f  different  origins.  Such  a  possibility  can  be  readily  seen
n  the  present  study,  as  a  dose  capable  of  controlling  neu-
opathic  hyperalgesia  did  not  achieve  the  same  results  as
hat  of  inﬂammatory  origin,  thus  demonstrating  the  need
or  further  studies  with  different  doses  of  the  drug.
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